Insight Molecular Diagnostics (IMDX) Share-based Compensation (2015 - 2026)

Insight Molecular Diagnostics has disclosed Share-based Compensation across 12 years of filings, most recently posting $615000.0 for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $615000.0, up 30.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (up 30.59% YoY), and the FY2025 annual result was $2.2 million, up 26.58% from the prior year.
• Share-based Compensation came in at $615000.0 for Q1 2026 at Insight Molecular Diagnostics, down from $721000.0 in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $3.2 million in Q3 2022 to a low of $386000.0 in Q2 2024.
• The 5-year median for Share-based Compensation is $608000.0 (2023), against an average of $1.0 million.
• Across the five-year window, Share-based Compensation soared 71.95% in 2022 and sank 81.52% in 2023, its largest moves.
• Insight Molecular Diagnostics' Share-based Compensation stood at $2.6 million in 2022, then tumbled by 81.52% to $484000.0 in 2023, then climbed by 3.1% to $499000.0 in 2024, then surged by 44.49% to $721000.0 in 2025, then decreased by 14.7% to $615000.0 in 2026.
• The last three Share-based Compensation figures came in at $615000.0 (Q1 2026), $721000.0 (Q4 2025), and $521000.0 (Q3 2025), per Business Quant data.